Our Founders
Our Founder & Co-Founder
OncoMenopause™ and the OncoMenopause Consortium®, founded by Lisa Larkin, MD, FACP, MSCP, IF, and co-founded by Maryam Lustberg, MD, MPH, is an education initiative of HERmedicine, a 501(c)(3) nonprofit dedicated to advancing evidence-based women's health.
Established to address the unique intersection of menopause and cancer survivorship, the Consortium strengthens multidisciplinary collaboration, advances clinical education, and supports the development of evidence-informed resources for individuals navigating menopause after cancer.
Lisa Larkin, MD, FACP, MSCP, IF
Lisa Larkin, MD, FACP, MSCP, IF, is a leader in internal medicine and women’s health with more than three decades of clinical experience and the unique perspective of being a breast cancer survivor. She is the founder of HERmedicine, a national 501(c)(3) nonprofit advancing evidence-based women’s health, and the founder and president of Ms.Medicine.
A Fellow of the American College of Physicians, a Certified Menopause Practitioner, and a Fellow of ISSWSH, Dr. Larkin maintains an active concierge internal medicine and women’s health practice focused on evidence-based care and long-term patient relationships.
She provides executive women’s health consultations and telemedicine services across multiple states, with expertise in menopause, sexual health, and preventive medicine. Dr. Larkin is recognized nationally for her leadership, innovation, and commitment to elevating standards of care in women’s health.
Maryam Lustberg, MD, MPH
Maryam Lustberg, MD, MPH, is a breast medical oncologist and serves as Chair of the OncoMenopause Education Committee and a member of the HERmedicine Board of Directors. She is currently Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven, Connecticut.
Dr. Lustberg is the co-chair of Symptom Intervention for the National Cancer Institute Alliance Clinical Trials and the immediate Past President of MASCC, an international organization dedicated to improving cancer supportive care worldwide. Her research focuses on biomarkers of therapeutic response and toxicity, cancer treatment symptom management, and the optimization of survivorship care.